Endonovo Therapeutics annual capital expenditures (capex)
2014
2015
2017
2018
2019
Endonovo Therapeutics Capital Expenditures (CapEx) Growth & History (ENDV)
Endonovo Therapeutics's capital expenditures (capex) was $2,594 for fiscal 2019.
View full Endonovo Therapeutics company overviewEndonovo Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2019 | 2019-12-31 | $2,594 | −$6,375 | −71.08% |
| 2018 | 2018-12-31 | $8,969 | −$3.0M | −99.70% |
| 2017 | 2017-12-31 | $3.0M | — | — |
| 2015 | 2015-12-31 | $3,829 | $3,829 | — |
| 2014 | 2014-12-31 | $0 | — | — |
Endonovo Therapeutics quarterly capital expenditures (capex)
Q1.18
Q2.18
Q3.18
Q4.18
Q3.19
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q3 2019 | 2019-09-30 | $723 | $723 | — |
| Q4 2018 | 2018-12-31 | $0 | — | — |
| Q3 2018 | 2018-09-30 | $0 | — | — |
| Q2 2018 | 2018-06-30 | $0 | — | — |
| Q1 2018 | 2018-03-31 | $8,969 | — | — |
Endonovo Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Endonovo Therapeutics's capital expenditures (capex) increased from $0 to $2,594, a change of $2,594. The latest reported quarter, Q3 2019, shows $723.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Endonovo Therapeutics source filings ↗